Hexarelin: The Complete Guide to the Most Potent GHRP

Hexarelin (examorelin) stands apart in the world of growth hormone peptides. As the most potent GHRP ever synthesized, it delivers exceptional growth hormone release — and it carries a second, entirely distinct superpower: direct cardioprotective action via the CD36 receptor, independent of any GH response. This guide covers everything researchers and clinicians need to know about hexarelin's mechanism, potency, dosing, side effects, and its unique cardiac profile.

What Is Hexarelin?

Hexarelin is a synthetic hexapeptide — six amino acids in length — classified as a growth hormone secretagogue (GHS) and growth hormone-releasing peptide (GHRP). It was developed in the 1990s as a potent synthetic analogue of ghrelin, the endogenous "hunger hormone" that also triggers growth hormone release.

Its formal INN (International Nonproprietary Name) is examorelin, and its sequence is His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2. The incorporation of D-amino acids at positions 2 and 5 makes it resistant to DPP-IV (dipeptidyl peptidase IV) enzymatic degradation — meaning it lasts far longer in circulation than native ghrelin, which is broken down within minutes.

Among all the GHRPs studied, hexarelin has consistently demonstrated the highest peak GH release, making it the benchmark by which other peptides in its class are measured.

Mechanism of Action: Dual Receptor Pharmacology

GHS-R1a: The GH-Releasing Pathway

Hexarelin's primary mechanism is agonism at the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein coupled receptor densely expressed on somatotroph cells in the anterior pituitary gland, as well as in the hypothalamus and limbic brain regions.

When hexarelin binds GHS-R1a, it activates the phospholipase C (PLC) signaling cascade, triggering production of inositol triphosphate (IP3) and a sharp rise in intracellular calcium. This calcium surge drives exocytosis of stored GH granules from pituitary somatotrophs, producing the characteristic GH pulse. This mechanism is entirely distinct from GHRH analogues like CJC-1295, which work through adenylyl cyclase/cAMP pathways — which is precisely why combining them produces synergistic results.

Hexarelin also suppresses somatostatin (the primary inhibitor of GH secretion), providing a secondary amplification effect on GH output.

CD36: The Cardiac Pathway

Hexarelin's second receptor target is CD36, a scavenger receptor highly expressed in cardiomyocytes and cardiac endothelial cells. This binding is completely independent of GHS-R1a and GH release. Studies in GH-deficient animals have confirmed that hexarelin's cardioprotective effects persist even when no GH response is possible — the cardiac action stands entirely on its own.

This dual pharmacology — GH-releasing via GHS-R1a, cardioprotective via CD36 — is unique to hexarelin among synthetic GHRPs and makes it a subject of active cardiovascular research.

Hexarelin vs. GHRP-2 vs. GHRP-6: Potency Comparison

Three GHRPs dominate the research literature: hexarelin, GHRP-2, and GHRP-6. Here is how they compare:

A landmark 1997 comparative study by Arvat et al. (European Journal of Endocrinology) directly compared GHRP-2 and hexarelin in humans and found both produced similar dose-dependent GH, prolactin, ACTH, and cortisol responses — with both significantly outperforming GHRH alone in GH amplitude. At equivalent doses, hexarelin showed a slight edge in peak GH response.

Versus GHRP-6, the gap is more dramatic: hexarelin releases approximately 10-fold more GH at equivalent doses, though it also comes with a steeper desensitization curve and more pronounced hormonal side effects.

Growth Hormone Release: What the Research Shows

The clinical data on hexarelin's GH-releasing effects is among the most robust of any synthetic GHRP:

• Onset: Measurable GH elevation within 15-30 minutes of subcutaneous injection
• Peak: Maximum serum GH at 30-60 minutes post-injection
• Route comparison: Hexarelin produces meaningful GH release via IV, SC, intranasal, and even oral routes — though bioavailability varies dramatically (SC ~77%, intranasal ~4.8%, oral ~0.3%)
• Age effects: GH response is greater in younger individuals. In GH-deficient patients, hexarelin's stimulatory response exceeded GHRH alone (Loche et al., 1995)
• IGF-1 elevation: One pediatric study documented IGF-1 rising from 10.4 to 14.1 nmol/L with hexarelin treatment, with linear growth velocity increasing from 5.3 to 8.3 cm/year

The half-life of hexarelin is approximately 55-70 minutes in humans following subcutaneous injection, making it suitable for 1-3x daily dosing protocols.

Hexarelin's Unique Cardioprotective Effects

This is where hexarelin truly distinguishes itself from every other GHRP. Its cardiac benefits operate through CD36 receptor agonism and have been validated across multiple independent research models.

Myocardial Infarction Protection

In acute MI mouse models, hexarelin treatment preserved cardiac function, resulting in higher ejection fraction and fractional shortening versus vehicle-treated controls. A 2018 PMC study (PMC5949285) confirmed hexarelin reduced cardiac fibrosis and preserved myocardial function following coronary artery ligation.

Anti-Apoptotic Effects

Hexarelin significantly decreased angiotensin II-induced apoptosis and DNA fragmentation in neonatal rat cardiomyocytes. It has also been shown to inhibit doxorubicin-induced cardiomyocyte death — a finding with potential implications for cardioprotection during chemotherapy.

Ejection Fraction Improvement in Healthy Humans

In a controlled study in healthy volunteers, hexarelin administration increased left ventricular ejection fraction (LVEF) from 64.0 +/- 1.5% to 70.7 +/- 3.0% (p < 0.03) without significant effects on blood pressure or heart rate.

Heart Failure and Remodeling

Chronic hexarelin administration alleviated left ventricular dysfunction and pathological cardiac remodeling in congestive heart failure rats. A 2020 study (PMC7018219) demonstrated the mechanism involved PTEN signaling pathway modulation — hexarelin attenuated heart failure induced by coronary artery ligation partly through PTEN downregulation.

Ischemia-Reperfusion Injury

Protection against cardiac damage from ischemia-reperfusion (IR) injury has been replicated in multiple independent animal models. A 2014 study (PubMed 24747279) found that a single oral dose of hexarelin protected chronic cardiac function post-MI — suggesting that even the poorly-bioavailable oral route may deliver meaningful cardiac effects via local GI/portal mechanisms.

A comprehensive 2014 review in Peptides (PMC4178518) summarized hexarelin's cardiovascular actions and identified the GHS-R1a/CD36 dual pharmacology as its defining mechanistic characteristic.

Dosing Protocols: Research Guidelines

The following reflects commonly used research dosing ranges based on published literature and investigator protocols. This is not medical advice.

Standard Dose Range

• Conservative: 100 mcg once daily SC
• Intermediate: 100-200 mcg, 1-2x daily (minimum 8 hours between injections)
• Maximum research dose: 200 mcg x 3 daily (e.g., morning, mid-afternoon, pre-sleep)

Timing Optimization

• Fast before injection: A 2-3 hour fast prior to dosing maximizes GH pulse amplitude. Elevated blood glucose blunts GHS-R1a signaling.
• Pre-sleep dosing: Aligns the GH pulse with the natural nocturnal GH surge during slow-wave sleep
• Pre-training: 30-45 minutes before exercise allows GH to peak during the workout window

Cycling to Manage Desensitization

Hexarelin's most significant limitation is its desensitization rate. Continuous GHS-R1a stimulation leads to receptor downregulation — the GH response can decline by 50-80% within just 2-4 weeks of daily use. Standard mitigation strategies:

• On/off cycles: 8-12 weeks on, followed by 4 weeks off
• Weekly structure: 5 days on, 2 days off
• Dose discipline: Doses above 200 mcg produce diminishing GH returns while disproportionately elevating cortisol and prolactin

Side Effects and Safety Considerations

Desensitization / Tachyphylaxis

As described above, rapid receptor desensitization is the dominant practical concern with hexarelin. This is substantially faster than with GHRP-2 and far faster than with ipamorelin, which was specifically engineered for selectivity and minimal desensitization.

Cortisol Elevation

Hexarelin stimulates ACTH-driven cortisol secretion. At doses of 0.5 mcg/kg, cortisol rises approximately 40%. At moderate doses this elevation is clinically modest; at high or chronic doses, it becomes pronounced and may offset some of the desired anabolic and recovery benefits of increased GH.

Prolactin Elevation

At 0.5 mcg/kg, prolactin increases approximately 80%. Chronically elevated prolactin can theoretically affect fertility and sex hormone balance. This is why many protocols favor cycling hexarelin or keeping doses conservative. A 1999 study (PubMed 10341859) confirmed that prolactin and pituitary-adrenal axis stimulation remained sustained with chronic hexarelin administration, even as the GH response habituated.

Other Side Effects

• Water retention: Mild, consistent with GH/IGF-1 elevation
• Fatigue/somnolence: Common around peak GH release, especially with pre-sleep dosing
• Hunger: Mild — less than GHRP-6 but present due to ghrelin receptor activity
• Tingling/flushing: Transient and injection-related

Stacking Hexarelin with CJC-1295

Combining hexarelin with a GHRH analogue like CJC-1295 (No DAC) is one of the most studied multi-peptide protocols in GH research. The synergy is mechanistically well-founded:

• CJC-1295 No DAC activates GHRH-R on pituitary somatotrophs, priming them for secretion via the cAMP pathway
• Hexarelin activates GHS-R1a via the PLC/calcium pathway and additionally suppresses somatostatin
• The combined GH pulse is 2-4x greater than either agent alone in research models

Typical stack dosing: CJC-1295 No DAC 100 mcg + Hexarelin 100-200 mcg, co-administered SC, 1-2x daily.

An important caveat: research has shown that repeated co-administration of hexarelin + GHRH leads to blunted synergy over time (PubMed 8762732), reinforcing the need for cycling. Many researchers who want sustained GH pulse amplitude with lower side-effect burden will substitute ipamorelin for hexarelin in long-running protocols, reserving hexarelin for shorter, higher-intensity cycles.

Administration and Storage

Route of choice: Subcutaneous injection (~77% bioavailability). Intranasal delivery (~4.8%) has been explored in some aging studies for convenience. Oral hexarelin is minimally bioavailable systemically for GH-stimulating purposes, though some cardiac research has found residual benefit via local gut/portal effects.

Reconstitution: Hexarelin is typically supplied as lyophilized (freeze-dried) powder. Reconstitute with bacteriostatic water (BAC water), typically 1-2 mL per vial.

Storage: Lyophilized powder is stable at room temperature short-term; store long-term in freezer. Once reconstituted, refrigerate and use within 30 days. Avoid repeated freeze-thaw cycles of the reconstituted solution.

Key Research Summary

Who Is Hexarelin For?

Among the synthetic GHRPs, hexarelin occupies a specific niche:

• Maximum GH output in short cycles: Hexarelin's unmatched potency makes it valuable for protocols prioritizing peak GH/IGF-1 elevation over extended periods. The desensitization issue limits its window but does not negate its short-term advantages.
• Cardiovascular research: Its CD36-mediated cardiac actions make it the most interesting peptide in the GHRP class for cardiac researchers, with a growing body of preclinical evidence supporting its role in cardiac protection and repair.
• GH-deficient populations: Clinical studies have shown hexarelin can meaningfully stimulate GH in patients who respond poorly to GHRH, suggesting it may fill gaps where GHRH analogues are insufficient.

Researchers who prefer longer, uninterrupted protocols with cleaner hormonal profiles typically favor ipamorelin. Those who want raw GH amplitude and are willing to cycle more aggressively — or who are specifically interested in cardiac applications — will find hexarelin the most compelling option in the GHRP family.

Conclusion

Hexarelin is the most potent synthetic GHRP ever characterized — a distinction it has held since its introduction in the 1990s. But what truly sets it apart is the secondary CD36-mediated cardioprotective mechanism, which has accumulated an impressive body of preclinical evidence spanning myocardial protection, anti-apoptosis, anti-fibrotic effects, and improvement in cardiac function following infarction.

Its practical limitations — rapid desensitization, cortisol and prolactin elevation, and the need for careful cycling — are real and require disciplined protocol design. But for researchers focused on short-cycle GH optimization or on cardiac applications specifically, hexarelin remains in a class of its own.

As with all research peptides, anyone considering hexarelin should do so under the guidance of a qualified healthcare provider and with a thorough understanding of the current regulatory and safety landscape.